Also trades as: 0UNL.L (LSE) · $vol 0M
NKTR NASDAQ
Nektar Therapeutics
1W: -3.2%
1M: -37.1%
3M: -46.3%
YTD: -12.6%
1Y: -36.8%
3Y: +390.6%
5Y: -84.8%
$37.97
+0.52 (+1.39%)
Pre-Market: $38.00 (+0.03, +0.07%)
Weekly Expected Move ±13.7%
$27
$32
$37
$42
$47
Credit Risk of going bust: higher than 66% of companies Debt: 11.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2024-03-04
Earliest Filing
2024-12-02
Latest Filing
acquirer: 2
partner: 1
investor: 1
Counterparties (Filed by NKTR)
4 relationshipsCompanies named in NKTR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ampersand Capital Partners | — | acquirer | Affiliate of Ampersand Management LLC that acquired Nektar's manufacturing facility and assets. | 2024-12-02 | View |
| Ampersand Capital Partners | — | acquirer | Purchaser of Nektar's manufacturing facility and assets for $90 million | 2024-11-04 | View |
| Ampersand Management LLC | — | partner | Parent entity of the Purchaser affiliate | 2024-11-04 | View |
| TCG Crossover Fund II, L.P. | — | investor | Purchased 25,000,000 pre-funded warrants for $30.0 million in a private placement. | 2024-03-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Regulation FD; Exhibits | View | |
| 2026-09-25 | Other Events | View | |
| 2026-09-08 | Regulation FD; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-05-08 | Material Agreement; Officer/Director Change; Exhibits | Agreement | View |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-23 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-04-20 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-20 | Regulation FD | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-13 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-02-10 | Regulation FD Disclosure | View | |
| 2026-02-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-27 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-16 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-21 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-18 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR